Very Long Versus Overlapping Stents in Long Coronary Lesions

Sponsor
The Young Investigator Group of Cardiovascular Research (Other)
Overall Status
Recruiting
CT.gov ID
NCT04738344
Collaborator
(none)
40
2
2
13.9
20
1.4

Study Details

Study Description

Brief Summary

This study is performed to compare the angiographic and clinical outcomes of the use of single long stent versus overlapping stents in the treatment of long coronary lesions in patients with chronic coronary syndrome.

Condition or Disease Intervention/Treatment Phase
  • Device: Percutaneous Coronary Intervention and Stent Implantation
N/A

Detailed Description

Percutaneous coronary intervention (PCI) in diffuse coronary artery disease is still considered a big obstacle for interventional cardiologists. Very long coronary lesions are usually found, and implantation of a single stent was a great problem forcing the operator to do overlapping of several stents.

Recently, new stent designs with increasing length are developed and emerging as a great tool for the percutaneous treatment of long lesions. Nowadays, stents up to 60 mm are available to be used in these cases reducing stent overlap.

Intravascular ultrasound (IVUS)-guided percutaneous coronary intervention has been shown in clinical trials, registries, and meta-analyses to be associated with a reduction in clinical events after percutaneous coronary intervention; however, IVUS utilization during percutaneous coronary intervention remains low in the United States and worldwide. The impact of IVUS in these complex lesions may be associated with a lower rate of clinical adverse events in comparison with angiography alone.

The study will be conducted on forty patients with chronic stable angina on maximal medical treatment who are going to have elective coronary angiography and elective PCI and having one long coronary lesion that is more than 40 mm in length, they will be randomized into either treatment of the lesion with a single very long stent (more than 40 mm in length) or with more than one overlapping stents in 1:1 randomization. Control angiography and IVUS will be done to the 2 groups after 6 months and the major cardiovascular outcomes will be addressed at 1,3 and 6 months follow-up periods.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
The Use of Very Long Versus Overlapping Drug Eluting Stents for the Management of Long Coronary Artery Lesions
Actual Study Start Date :
Jan 1, 2021
Anticipated Primary Completion Date :
Jan 1, 2022
Anticipated Study Completion Date :
Mar 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Percutaneous coronary intervention and stent implantation using one long stent

Long coronary lesions will be treated percutaneously with a single long stent (more than 40 mm in length) and intravascular ultrasonography (IVUS) will be done immediately after stent deployment to record the baseline picture

Device: Percutaneous Coronary Intervention and Stent Implantation
Percutaneous Coronary Intervention and Stent Implantation will be implanted as recommended by guidelines and according to the standard techniques.
Other Names:
  • PCI
  • Experimental: Percutaneous coronary intervention and stent implantation using more than one overlapping stents

    Long coronary lesions will be treated with more than one overlapping stents and intravascular ultrasonography (IVUS) will be done immediately after stent deployment to record the baseline picture

    Device: Percutaneous Coronary Intervention and Stent Implantation
    Percutaneous Coronary Intervention and Stent Implantation will be implanted as recommended by guidelines and according to the standard techniques.
    Other Names:
  • PCI
  • Outcome Measures

    Primary Outcome Measures

    1. Coronary angiographic criteria after 6 months of stent deployment [6 months]

      Number of participants with any form in-stent restenosis using control coronary angiography at 6 months

    2. (IVUS) after 6 months of stent deployment [6 months]

      Number of participants with any form in-stent restenosis using Intravascular Ultrasonography (IVUS) at 6 months to assess subclinical neointimal proliferation and in-stent restenosis

    3. Major Cardiovascular and Cerebrovascular Events (MACCE) after 6 months [6 months]

      Number of patients with any Major Cardiovascular and Cerebrovascular Events (MACCE) at 6 months of stent deployment

    Secondary Outcome Measures

    1. Any Major Bleeding Event [6 months]

      Number of patients with Any Major Bleeding Event as defined by the International Society of Thrombosis and Haemostasis (fatal bleeding, and/or symptomatic bleeding in a critical organ or area, and/or bleeding causing a fall in hemoglobin level of ≥ 2 g/dl or 1.24 mmol/L

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients > 18 years of age

    • Single vessel disease and undergoing PCI for significant long lesion.

    • Chronic stable angina on maximal medical treatment.

    Exclusion Criteria:
    • Patients presenting with acute coronary syndromes.

    • Patients having two or more vessel disease on coronary angiography.

    • Previous myocardial infarction.

    • Previous vascularization either by PCI or bypass grafting.

    • Very low ejection fraction less than 35%.

    • Renally impaired patients with Creatinine clearance less than 50 ml/min.

    • Contraindication to dual antiplatelet drug therapy.

    • Contraindication to coronary angiography.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Alexandria Alexandria Egypt 21321
    2 International Cardiac Center (ICC) Alexandria Egypt 21524

    Sponsors and Collaborators

    • The Young Investigator Group of Cardiovascular Research

    Investigators

    • Study Chair: Mohamed A Sobhy, MD, University of Alexandria - Egypt
    • Study Director: Amr Zaky, MD, University of Alexandria - Egypt
    • Principal Investigator: Ahmed M El Amrawy, MD, University of Alexandria - Egypt

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    The Young Investigator Group of Cardiovascular Research
    ClinicalTrials.gov Identifier:
    NCT04738344
    Other Study ID Numbers:
    • YIG0122001
    First Posted:
    Feb 4, 2021
    Last Update Posted:
    Jul 8, 2021
    Last Verified:
    Jul 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by The Young Investigator Group of Cardiovascular Research
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 8, 2021